MeiraGTx Holdings stock (US58550P1012): Insider selling draws attention as gene therapy story evolve
MeiraGTx Holdings is a gene therapy specialist focused on inherited retinal diseases and neurology, operating a vertically integrated platform with its own manufacturing facilities. CEO Alexandria Forbes recently sold 62,000 shares, adding to the stock's volatility. Despite the insider sale, the company's long-term value is expected to be driven primarily by progress in clinical trials, regulatory milestones, and collaboration advancements.
Insider Sell Alert: Alexandria Forbes Sells 62,000 Shares of MeiraGTx Holdings PLC (MGTX)
Alexandria Forbes, President & CEO of MeiraGTx Holdings PLC, sold 62,000 shares of the company on May 19, 2026, bringing her total ownership to 1,387,695 shares. Over the past year, Forbes has sold 219,000 shares with no purchases, and the company has seen eight insider sells and no buys. MeiraGTx Holdings PLC (MGTX) is currently trading at $9.17 with a price-to-GF-Value ratio of 0.4, suggesting it might be a "Possible Value Trap."
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares
MeiraGTx Holdings plc President & CEO Forbes Alexandria sold 62,000 shares of the company's stock for a total of $568,540 on May 19, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred while the company's stock saw a 66% return over the past year, with ongoing profitability challenges despite recent positive developments like strategic collaborations and increased price targets from analysts. Ms. Forbes now directly holds 1,387,695 ordinary shares.
MeiraGTx (MGTX) CEO sells 62,000 shares under Rule 10b5-1 plan
MeiraGTx Holdings plc CEO Alexandria Forbes sold 62,000 Ordinary Shares on May 19, 2026, at a
MGTX (NASDAQ) affiliate lists 62,000-share sale in Form 144 filing
MeiraGTx Holdings plc (MGTX) has filed a Form 144 notice indicating a proposed sale of 62,000 ordinary shares. The filing references an Incentive Compensation Stock Grant from June 7, 2018, and a sale recorded on March 24, 2026, with an individual named Alexandria Forbes listed as the seller. This notice serves as a standard disclosure for affiliates planning to sell securities.
MeiraGTx Holdings stock (US58550P1012): gene therapy player in focus after recent earnings and partnership updates
MeiraGTx Holdings is a Nasdaq-listed clinical-stage gene therapy company focused on developing treatments for serious diseases, particularly in ophthalmology, neurology, and salivary gland disorders. The company's revenue primarily comes from collaboration agreements, notably with Janssen, and it recently reported its first-quarter 2026 results. For US investors, MeiraGTx offers exposure to the high-growth gene therapy segment, with future value tied to clinical data, regulatory decisions, and partnership developments rather than current earnings.
MeiraGTx Holdings plc (NASDAQ:MGTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
MeiraGTx Holdings plc recently reported first-quarter results that did not meet analyst expectations, with revenues significantly lower and a per-share loss of US$0.57. Following these results, analysts have updated their forecasts for 2026, anticipating a substantial revenue decline to US$49.5 million and increased per-share losses of US$1.65. Despite these changes, the consensus price target remains at US$28.25, indicating that the reduced loss estimates were not enough to positively impact the long-term stock valuation.
MGTX Maintained by RBC Capital -- Price Target Raised to $25.00
RBC Capital has maintained its 'Outperform' rating for MeiraGTx Holdings (MGTX) and increased its price target to $25.00 from $24.00, signaling continued confidence despite the stock trading significantly below this target. However, GuruFocus indicates MGTX has an average GF Score of 50 and highlights recent insider selling activity of $1.3 million, suggesting potential challenges for investors to consider. The company, a biotechnology firm, is valued as undervalued by GuruFocus, but also shows low financial strength and profitability scores.
RBC Raises Price Target on MeiraGTx Holdings to $25 From $24, Keeps Outperform, Speculative Risk
RBC Capital Markets has raised its price target for MeiraGTx Holdings
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
MeiraGTx announced its financial and operational results for the first quarter ended March 31, 2026, highlighting the reacquisition of full rights to botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP) and the FDA Breakthrough Therapy Designation for AAV2-hAQP1. The company strengthened its balance sheet with a $100 million financing and reported a net loss of $46.3 million for the quarter.
MeiraGTx (MGTX) CDO awarded 100,000 RSUs and 100,000 stock options
MeiraGTx Holdings plc's Chief Development Officer, Penny Renee Fleck, was granted 100,000 restricted share units (RSUs) and 100,000 stock options. The stock options have an exercise price of $9.97 per share and an expiration date of May 1, 2036, with vesting occurring over several years. This compensation-related equity grant aligns her incentives with the company's performance, adding to her potential future ownership.
MeiraGTx (MGTX) Chief Development Officer listed as insider in new Form 3
MeiraGTx Holdings plc's Chief Development Officer, Penny Renee Fleck, has been listed as an insider in a new Form 3 filing. This initial statement of beneficial ownership indicates her status as a reporting officer but shows no reported transactions, derivative positions, or holdings in this specific filing. The Form 3 serves as a baseline disclosure, establishing her as a Section 16 reporting person for future security transactions.
Earnings Flash (MGTX) MeiraGTx Holdings Plc Reports Q1 Revenue $0.3M, Vs. FactSet Est of $17.0M
MeiraGTx Holdings Plc (MGTX) reported its Q1 revenue at $0.3 million, significantly missing the FactSet estimate of $17.0 million. This earnings flash highlights a substantial revenue shortfall for the company in the first quarter.
MeiraGTx Holdings Releases Q1 2026 Financial Results
MeiraGTx Holdings plc reported a net loss of $46.3 million, or $0.57 per share, for Q1 2026, widening from $0.51 per share in the prior year. Revenue significantly declined to $293,000 from $1.9 million in Q1 2025. Despite these financial results, Wall Street analysts maintain a largely bullish outlook with 9 buy ratings, 1 hold, and no sell recommendations, reflecting confidence in the company's long-term potential in genetic medicines.
Earnings Flash (MGTX) MeiraGTx Holdings plc Reports Q1 Revenue $0.3M, vs. FactSet Est of $17.0M
MeiraGTx Holdings plc (MGTX) announced Q1 revenue of $0.3 million, significantly missing FactSet's estimated $17.0 million. This news was released on May 14, 2026, and is reserved for members of MarketScreener. The company specializes in genetic medicines with a pipeline of clinical programs for various diseases.
MeiraGTx Holdings plc 1Q 2026: Revenue $293K, EPS ($0.57) — 10-Q Summary
MeiraGTx Holdings plc reported its first-quarter 2026 results, showing a significant year-over-year revenue decrease to $293K and an adjusted net loss per share of ($0.57). The company continued advancing its pipeline with four late-stage programs, including the pivotal AQUAx2 study, and secured strategic partnerships with Lilly and Hologen. MeiraGTx also reacquired bota-vec from Janssen and maintained in-house GMP manufacturing, pursuing regulatory filings in multiple regions.
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
MeiraGTx announced its financial and operational results for the first quarter ended March 31, 2026, highlighting significant strategic achievements. Key updates include receiving FDA Breakthrough Therapy Designation for AAV2-hAQP1, re-acquiring botaretigene sparoparvovec (bota-vec) for XLRP, and strengthening its balance sheet with a $100 million financing. The company plans to expedite regulatory submissions for bota-vec and progress its clinical programs, including AAV2-hAQP1 and AAV-GAD, while also advancing its riboswitch gene regulation technology.
Adage Capital (MGTX) reports 4,000,000-share holding, 4.91% stake
Adage Capital Management, L.P. and its associated reporting persons, Robert Atchinson and Phillip Gross, have disclosed a collective 4,000,000 Ordinary Shares in MeiraGTx Holdings plc (MGTX), representing a 4.91% stake. This information comes from an Amendment No. 6 to a Schedule 13G SEC filing. The percentage is based on 81,446,126 Ordinary Shares outstanding as of March 30, 2026, with shared voting and dispositive power attributed to the reporting parties.
MeiraGTx Holdings stock (US58550P1012): Q1 earnings report due May 12
MeiraGTx Holdings (MGTX) is scheduled to release its Q1 2026 earnings report today, with analysts expecting an EPS of -$0.17. The clinical-stage biotech focuses on gene therapies for rare diseases, with its shares trading at $9.94 on Nasdaq, up 0.36%. The report will provide updates on its gene therapy pipeline and financial health, as the company operates in the rapidly growing AAV gene therapy market.
Number of shareholders of MeiraGTx Holdings Plc – LS:A2JGHF
This article provides access to financial information for MeiraGTx Holdings Plc, identified by the stock symbol A2JGHF on the Lang & Schwarz Tradecenter. It specifically highlights the "Number of shareholders" data, which is presented alongside other financial metrics and market data provided by various financial services. The content is primarily a data portal entry, with no additional textual analysis.
Avoiding Lag: Real-Time Signals in (MGTX) Movement
This article provides a real-time analysis of Meiragtx Holdings Plc (NASDAQ: MGTX) stock, highlighting a strong near-term sentiment within a long-term bullish context, despite a mid-term weak bias. It outlines an exceptional risk-reward short setup and offers three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
[ARS] MeiraGTx Holdings plc SEC Filing
MeiraGTx Holdings plc (MGTX) has filed an ARS form with the SEC, indicating a low impact and neutral sentiment. The filing, available as a PDF document, was accepted on April 30, 2026, at 8:16 AM. This report also provides an overview of MGTX's stock data, rankings, and recent news, including a $100 million offering of ordinary shares and positive clinical trial data.
MeiraGTx (NASDAQ: MGTX) details pay and board votes for 2026 AGM
MeiraGTx Holdings plc has issued its definitive proxy statement (DEF 14A) for its 2026 virtual annual meeting on June 11, 2026. Shareholders will vote to elect three Class II directors and ratify Ernst & Young LLP as the independent auditor. The proxy statement also details 2025 executive compensation, with CEO Alexandria Forbes receiving $8.33 million.
MeiraGTx (MGTX) CMO amends Form 4 for 7,814 tax-withheld shares
MeiraGTx Holdings plc's Chief Medical Officer, Robert K. Zeldin, filed an amended Form 4 to correct an administrative error regarding tax-withheld shares. The filing states that 7,814 Ordinary Shares were withheld for tax payments at a value of $7.73 per share upon the vesting of an award. Following this adjustment, Mr. Zeldin beneficially owns 146,204 Ordinary Shares directly, with a minor correction for prior rounding errors.
DAVENPORT & Co LLC Purchases 7,000 Shares of MeiraGTx Holdings Plc (NASDAQ:MGTX)
DAVENPORT & Co LLC increased its stake in MeiraGTx Holdings Plc (NASDAQ:MGTX) by 27.5% during the 4th quarter, purchasing an additional 7,000 shares to own a total of 32,500 shares valued at approximately $180,000. Other institutional investors have also adjusted their positions in MGTX. The company's stock last traded at $5.76, having seen a 52-week low of $3.29 and a 52-week high of $12.30.
Discipline and Rules-Based Execution in MGTX Response
This article from Stock Traders Daily discusses AI-generated trading strategies for Meiragtx Holdings Plc (NASDAQ: MGTX). It identifies weak near-term sentiment but strong mid- and long-term signals, highlighting a significant risk-reward setup. The piece details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis for MGTX.
MeiraGTx and Hologen finalize collaboration and licensing agreements
MeiraGTx and Hologen have finalized collaboration and licensing agreements for the research, development, manufacturing, and commercialization of gene therapies for Parkinson’s disease and genetic obesity disorders. The deal includes a $200 million upfront cash commitment from Hologen, with $105 million already paid, and will result in Hologen holding a significant stake in Hologen Neuro AI Limited. This strategic partnership addresses MeiraGTx's short-term financial needs while advancing its gene therapy pipeline.
Perceptive lifts MeiraGTx (NASDAQ: MGTX) ownership to 12.6% with warrants
Perceptive Advisors and its affiliates now beneficially own 12.6% of MeiraGTx (NASDAQ: MGTX) ordinary shares, totaling 11,742,117 shares. This stake includes a recent purchase of 555,555 shares at $9.00 each on April 17, 2026, and warrants for 700,000 shares which had their exercise price adjusted from $15.00-$20.00 to $8.00 per share on March 25, 2026. This significant ownership combines equity and credit exposure, underlining Perceptive's ongoing investment in MeiraGTx.
MeiraGTx Holdings (NasdaqGS:MGTX) Stock Forecast & Analyst Predictions
MeiraGTx Holdings (MGTX) is forecast to grow earnings and revenue by 26% and 39.8% per annum, respectively, with an expected EPS growth of 29% per annum. Eight analysts have increased the average price target to US$27.88, which is 178% above the last closing price. The company recently announced positive three-year data from its Phase 1 AQUAx clinical study for radiation-induced xerostomia and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for Parkinson's disease.
MeiraGTx and Hologen finalize collaboration and licensing agreements
MeiraGTx and Hologen Limited have finalized a strategic collaboration involving the research, development, manufacturing, and commercialization of gene therapies for Parkinson’s disease and genetic obesity disorders. Hologen will make a $200 million upfront cash payment commitment, with a portion already paid and the remainder to be funded through additional share purchases. This collaboration addresses MeiraGTx's critical cash needs and involves Hologen acquiring a minority interest in MeiraGTx Manufacturing Limited, with options for increased ownership.
MeiraGTx acquires J&J's XLRP investigational therapy
MeiraGTx Holdings plc has acquired all interests in Johnson & Johnson's investigational gene therapy, botaretigene sparoparvovec (bota-vec), for X-linked retinitis pigmentosa (XLRP). The therapy, which had previously failed its primary endpoint in a Phase 3 study but showed strong secondary endpoint data, will now be advanced by MeiraGTx. MeiraGTx plans to expeditiously file for regulatory approval in the US, EU, and Japan, targeting a 2027 launch, with the acquisition deal including an upfront cash payment and future royalties.
MeiraGTx (NASDAQ: MGTX) details $200M Hologen CNS gene therapy pact
MeiraGTx (NASDAQ: MGTX) has detailed a strategic collaboration and license agreement with Hologen for CNS gene therapies and a proprietary delivery device. The partnership includes an upfront cash payment commitment of $200 million, with $105 million already received and partially used for funding MeiraGTx Neuro US and subscribing for shares in Hologen Neuro AI Limited (HNAI) and MeiraGTx Manufacturing Limited. Hologen is expected to own 70% of HNAI post-completion, and will have an option to increase its ownership in MeiraGTx Manufacturing up to 40%.
MeiraGTx (MGTX) Perceptive funds gain $8 warrants and new shares
Perceptive Advisors, through its associated funds, has adjusted its positions in MeiraGTx Holdings plc (MGTX). Perceptive Life Sciences Master Fund Ltd. received a grant of 555,555 Ordinary Shares at $9.00, increasing its indirect holdings to 10,786,658 shares. Additionally, Perceptive Credit Holdings III, LP received new warrants for 700,000 Ordinary Shares with an $8.00 exercise price, while disposing of older warrants with higher exercise prices as part of a financing agreement adjustment.
Richard Giroux Sells 56,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
Richard Giroux, CFO of MeiraGTx Holdings PLC, sold 56,000 shares of MGTX stock for over $572,000 as part of a pre-arranged Rule 10b5-1 plan, reducing his stake by 5.45%. Despite this insider sale, the company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue, though it remains unprofitable. Analysts generally maintain a "Moderate Buy" rating with an average price target of $25.00 for the stock.
Piper Sandler raises MeiraGTx stock price target to $30 on data
Piper Sandler has increased its price target for MeiraGTx Holdings plc (MGTX) to $30 from $26, maintaining an Overweight rating, citing promising three-year data for its xerostomia treatment and the reacquisition of the bota-vec gene therapy. The company has also completed a $100 million equity raise to extend its cash runway. These developments have led to other analysts, including RBC Capital and H.C. Wainwright, also raising their price targets for MGTX.
Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone
MeiraGTx Holdings Plc (MGTX:NASDAQ) has reported positive 3-year gene therapy results for AAV-hAQP1, demonstrating sustained efficacy for radiation-induced xerostomia. The company also secured approximately $100 million in funding through an underwritten offering, which will help advance its late-stage pipeline, including the reacquired ophthalmology asset bota-vec towards potential commercial launches by 2028. Analysts have issued "Buy" ratings for MGTX, citing its robust pipeline and clear path to commercialization, positioning it in a rapidly growing gene therapy market.
[144] MeiraGTx Holdings plc SEC Filing
This SEC filing (Form 144) for MeiraGTx Holdings plc details a proposed sale of 56,000 ordinary shares acquired through incentive compensation stock grant on June 7, 2018. The shares, valued at $572,545, are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of April 21, 2026. The filing indicates a neutral impact and sentiment.
MeiraGTx CFO & COO Richard Giroux sells $572,320 in stock
Richard Giroux, CFO and COO of MeiraGTx Holdings plc, sold 56,000 ordinary shares for $572,320 on April 21, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred after a challenging week for the company's shares. Despite other recent positive news like a $100 million share offering and reacquiring a gene therapy, Mr. Giroux continues to hold a significant number of shares, both directly and indirectly.
MeiraGTx (MGTX) CFO sells 56,000 shares under 10b5-1 plan
MeiraGTx Holdings plc's CFO & COO, Richard Giroux, sold 56,000 Ordinary Shares at a weighted average price of $10.22 per share, totaling $572,320. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the sale, Giroux directly holds 971,530 Ordinary Shares and indirectly holds an additional 90,152 shares through an LLC and his spouse.
Latham & Watkins Represents MeiraGTx in US$100 Million Ordinary Shares Offering
Latham & Watkins LLP represented MeiraGTx Holdings plc (Nasdaq: MGTX) in an underwritten offering of 11,111,111 ordinary shares at US$9 per share, totaling approximately US$100 million in gross proceeds. The offering closed on April 17, 2026, with all shares sold by MeiraGTx. A corporate team from Latham & Watkins, led by partners Keith Halverstam and Jennifer Yoon, advised on the transaction, with additional counsel on healthcare, FDA, and investment adviser regulatory matters.
H.C. Wainwright reiterates MeiraGTx stock rating on gene therapy progress By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for MeiraGTx Holdings (NASDAQ:MGTX), citing positive gene therapy progress. The firm highlighted strong 36-month AQUAx study data for AAV-hAQP1, the regaining of full control over the bota-vec asset, and a recent $100 million financing round that funds operations through late 2028. These developments, along with recent pricing of a share offering and positive data, support the optimistic outlook despite the company not yet being profitable.
MeiraGTx Announces Public Equity Offering to Fund Growth
MeiraGTx Holdings plc announced a public offering of 11,111,111 ordinary shares at $9.00 each, aiming to raise approximately $93.3 million in net proceeds. The funds will support general corporate purposes, including working capital, capital expenditures, and potential commercial launches of lead gene therapy candidates through the second half of 2028. Analysts currently rate MGTX stock as a Buy with an $18.00 price target, though TipRanks' AI Analyst notes financial weaknesses alongside strong technical momentum and pipeline developments.
MeiraGTx (NASDAQ:MGTX) Sees Unusually-High Trading Volume on Analyst Upgrade
MeiraGTx (NASDAQ:MGTX) experienced unusually high trading volume after Royal Bank of Canada upgraded its rating to "outperform" and increased its price target from $16 to $24. The company has also strengthened its pipeline by acquiring bota-vec for X-linked retinitis pigmentosa and reported positive three-year Phase 1 AQUAx data. Despite recent insider stock sales and a dilutive share offering, institutional investors have increased their holdings, and the stock is currently trading up 7.1%.
Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions
Evercore ISI analyst Gavin Clark-Gartner maintained an Outperform rating on MeiraGTx Holdings plc (MGTX), though he reduced the price target from $20 to $18 due to broader sector revisions and upcoming Q2 catalysts. The company recently received Breakthrough Therapy Designation from the FDA for its AAV2-hAQP1 program, strengthening its regulatory position for treating xerostomia from radiotherapy. MeiraGTx is a clinical-stage biotechnology company focused on gene therapies for serious diseases.
RBC Capital raises MeiraGTx stock price target to $24 on xerostomia data
RBC Capital has raised its price target for MeiraGTx Holdings plc (NASDAQ:MGTX) to $24 from $16, maintaining an Outperform rating, due to positive three-year follow-up data from its xerostomia program and the reacquisition of its XLRP program from Johnson & Johnson. The biotech company also completed a $100 million equity raise, extending its financial runway into the second half of 2028. Analysts suggest the stock is undervalued, with price targets potentially reaching $50.
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
MeiraGTx Holdings plc has reacquired the rights to bota-vec, a treatment for X-linked retinitis pigmentosa, from Johnson & Johnson through an asset purchase agreement. The company aims to expedite regulatory filings for bota-vec, targeting a potential launch in 2027, and recently completed a $100 million public offering to extend its funding runway into the second half of 2028. This move follows a previous deal where MeiraGTx granted Eli Lilly exclusive rights to another one of its genetic eye disease programs.
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
MeiraGTx announced positive three-year data from its Phase 1 AQUAx clinical study of AAV-hAQP1 for treating late radiation-induced xerostomia (RIX). The data showed sustained, clinically meaningful improvements in xerostomia symptoms and unstimulated saliva flow rates. The company highlights AAV-hAQP1 as a potential one-time, disease-modifying treatment for this debilitating condition.
MeiraGTx (NASDAQ: MGTX) raises $93.3M net in new share sale
MeiraGTx Holdings plc has announced an underwritten public offering of 11,111,111 ordinary shares at $9.00 per share, expecting to raise approximately $93.3 million in net proceeds. These funds, combined with existing cash, are projected to cover operating and capital needs, including potential commercial launches of bota-vec and AAV-hAQP1 if approved, into the second half of 2028. The offering was conducted under an effective shelf registration statement, with BofA Securities and Goldman Sachs & Co. LLC acting as underwriters.
MeiraGTx (NASDAQ: MGTX) raises ~$99.9M via 11.11M-share offering
MeiraGTx Holdings plc (NASDAQ: MGTX) has announced an offering of 11,111,111 ordinary shares at $9.00 per share, aiming to raise approximately $99.9 million in gross proceeds. After underwriting discounts and commissions, the estimated net proceeds to the company are about $93.3 million, which will be used for general corporate purposes, including working capital and capital expenditures. This offering will result in an immediate dilution of $8.23 per share for new investors, bringing the post-offering net tangible book value to $0.77 per share compared to a pre-offering value of $(0.27) per share.
According to the latest filings disclosed by the US Securities and Exchange Commission, Johnson & Johnson and its subsidiary JJDc have reached a significant agreement with gene therapy company MeiraGTx Holdings Plc.
Johnson & Johnson and its subsidiary JJDc have finalized an agreement with gene therapy company MeiraGTx Holdings Plc, as revealed in recent SEC filings. This agreement includes a 12-month lock-up period for MeiraGTx shares held by relevant parties after the transaction, aiming to demonstrate confidence in the company's long-term growth and ensure share price stability. The lock-up signifies a deeper strategic collaboration between the two companies, with MeiraGTx specializing in novel treatments for severe diseases.
